Navigation Links
InSphero’s New EU Subsidiary Opens for Business

Schlieren, Switzerland (PRWEB) November 26, 2013

In September 2013, InSphero, a leading supplier of organotypic, biological, in vitro 3D microtissues for highly predictive drug testing based in Switzerland, opened a fully owned subsidiary just over the border in Waldshut, Germany, to cater towards its customers within the European Union. Following the successful launch of the company’s US office back in April, the new European branch aims to serve InSphero’s growing number of customers from the European Union more effectively and expand its EU business, which has always represented an important target market.

The idea of the subsidiary is to speed up the purchasing process and make it easier for InSphero’s customers in the EU. The company’s 3D InSight™ Microtissues and GravityPLUS™ 3D Cell Culture Kits will now be delivered to customers without customs clearance delays and with lower shipping costs than when microtissues were shipped from the InSphero headquarters in Switzerland.

“Our European customers really appreciate the fact that they are now able to obtain our InSphero 3D cell culture products for their assays within twenty-four hours, without them getting held up at customs,” explains Björn Niggemann, Head of Operations at InSphero, who is also responsible for export and distribution and since September has successfully been processing shipments through this new channel with his team. “And apart from anything else, customers also stand to benefit from 15-20% lower shipping costs.”

On the back of all these advantages for the customer, the new office is bound to boost sales this side of the Atlantic.

About InSphero
InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards and is also certified to the ISO 9001:2008 standard for its Quality Management System.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Mendel Biotechnology to sell its subsidiary, Mendel Plant Sciences
2. The Renewable Corporation (RNWB) through its wholly owned subsidiary EcoSmart Surface & Coating Technologies receives results from Product Test Service.
3. XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
4. New England Biolabs opens seventh subsidiary in Singapore
5. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
6. Union Equity, Inc.s Wholly Owned Subsidiary Develops Cream that Aids in Soothing the Symptoms of Chemotherapy
7. AquaLiv Technologies, Inc. and Its Subsidiary, AquaLiv, Inc., Release Funding Updates
8. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
9. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
10. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
11. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
Post Your Comments:
(Date:10/12/2015)... , Oct. 12, 2015 VolitionRx Limited ... a completed clinical study of its NuQ ® blood-based ... the online issue of Clinical Epigenetics , the official ... conducted in collaboration with Lund University, ... Andersson , MD, PhD, Professor of Surgery and Vice-Dean, Faculty ...
(Date:10/11/2015)... ... October 11, 2015 , ... ... has been officially launched and multiple surgeries have been completed with this new ... of the Neuroscience & Spine Center of the Carolinas. The Revolution™ Spinal ...
(Date:10/9/2015)... -- Governor Tom Wolf announced today that ... developing T-cell receptor cancer immunotherapy treatments, will create at ... project. Pennsylvania , and today,s ... new, high-paying jobs will be created with this project," ... includes sustained funding for the life science sector and ...
(Date:10/9/2015)... ... October 09, 2015 , ... From blood to food ... those cells from their surroundings for research, diagnostics, and cell therapy—also known as ... this, Ann Arbor-based startup Akadeum Life Sciences is developing a radically ...
Breaking Biology Technology:
(Date:10/5/2015)... ) releases ... (NASDAQ: NXTD ), a biometric authentication company focused ... ) releases the following market and ... a biometric authentication company focused on the growing mobile ... ) releases the following market and ...
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court of ... another key ruling in favor of Crossmatch ™, ... fingerprint scanner company Suprema and its U.S. partner Mentalix ... a trade provision that declares it unlawful to engage ... infringing two of Crossmatch,s patents, the 5,900,993 patent and ...
Breaking Biology News(10 mins):